Search ↗

Comparison

BPC-157 vs Pentosan Polysulfate

Both are healing & repair, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, Pentosan Polysulfate is the better documented of the two (regulator approved). That is a statement about the state of the literature, not a recommendation.

BPC-157 Pentosan Polysulfate
Class Healing & repair Healing & repair
Evidence Animal models only Regulator approved
Human trials None published ~25
Half-life ~4 hours ~4-5 hours
Reported range 200-500 mcg 100-300 mg
Frequency 1-2x daily, often near the injury site 3x daily (oral, approved use)
Routes Subcutaneous, Oral, Intramuscular Oral, Subcutaneous
FDA approved No Yes
Research use only Yes No
Banned in sport Yes No
Studied for Tendon and ligament injury research, Gastrointestinal healing research, Soft tissue repair Interstitial cystitis, Bladder pain syndrome, Osteoarthritis research
Reported side effects Injection-site reactions, Transient nausea, Headache, Dizziness Pigmentary maculopathy with long-term use, Diarrhoea, Nausea, Headache, Alopecia

BPC-157

BPC-157 is a stable 15-amino-acid sequence derived from body protection compound, a protein found in human gastric juice. Animal work reports accelerated healing across tendon, ligament, muscle, bone and gastrointestinal tissue, with proposed mechanisms including upregulation of VEGF-driven angiogenesis, modulation of the nitric oxide system, and increased fibroblast migration and growth-factor receptor expression. The evidence base is almost entirely rodent. No adequately powered human trial has been published, which is the central fact about this compound and should lead every page about it.

Pentosan Polysulfate

Pentosan polysulfate sodium is a sulfated polysaccharide, not a peptide, structurally similar to glycosaminoglycans. It is thought to restore the deficient glycosaminoglycan layer of the bladder urothelium, reducing permeability to irritants in interstitial cystitis. It also has weak anticoagulant activity. Long-term use has been associated with a distinctive retinal pigmentary maculopathy, added to the Warnings and Precautions section of the US label in 2020, which has substantially changed prescribing practice.

BPC-157 vs Pentosan Polysulfate: common questions

What is the difference between BPC-157 and Pentosan Polysulfate?

Both are healing & repair. BPC-157: A synthetic pentadecapeptide derived from a gastric protein, and the most searched compound in the peptide category. Pentosan Polysulfate: An FDA-approved semi-synthetic polysaccharide for bladder pain, with a label warning about retinal damage (pigmentary maculopathy) with long-term use.

Which has stronger evidence, BPC-157 or Pentosan Polysulfate?

Pentosan Polysulfate has the stronger evidence base (regulator approved, about 25 human studies) compared with BPC-157 (animal models only).

Are BPC-157 and Pentosan Polysulfate FDA approved?

Only Pentosan Polysulfate is FDA approved (Bladder pain or discomfort associated with interstitial cystitis (Elmiron)). BPC-157 is not approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 9941957) ↗ · structure, identifiers, synonyms
  2. WADA Prohibited List ↗ · current year
  3. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  4. CAS Registry Number 137525-51-0 ↗ · chemical identity
  5. PubChem compound record (CID 92043424) ↗ · structure, identifiers, synonyms
  6. DailyMed: FDA-approved labeling for Pentosan Polysulfate ↗ · indications, dosing, warnings as approved
  7. FDA Drugs@FDA database ↗ · approval history
  8. CAS Registry Number 116001-96-8 ↗ · chemical identity

Published literature

  1. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.Cell Tissue Res 2019.PubMed 30915550 · doi:10.1007/s00441-019-03016-8
  2. Seiwerth S, Rucman R, Turkovic B, et al.. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.Curr Pharm Des 2018.PubMed 29998800 · doi:10.2174/1381612824666180712110447
  3. Mayfield CK, Bolia IK, Feingold CL, et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
  4. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  5. DeFoor MT, Dekker TJ. Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?.Arthroscopy 2025.PubMed 39265666 · doi:10.1016/j.arthro.2024.09.005
  6. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  7. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890
  8. Seiwerth S, Brcic L, Vuletic LB, et al.. BPC 157 and blood vessels.Curr Pharm Des 2014.PubMed 23782145 · doi:10.2174/13816128113199990421
  9. Lindeke-Myers A, Hanif AM, Jain N. Pentosan polysulfate maculopathy.Surv Ophthalmol 2022.PubMed 34000253 · doi:10.1016/j.survophthal.2021.05.005
  10. Siddiq MAB, Oo WM, Hunter DJ. New therapeutic strategies in osteoarthritis.Joint Bone Spine 2024.PubMed 38685527 · doi:10.1016/j.jbspin.2024.105739
  11. Andreeva NA, Sheremet NL. [Peripapillary pachychoroid syndrome].Vestn Oftalmol 2024.PubMed 39731248 · doi:10.17116/oftalma2024140061138
  12. Trojan DA, Cashman NR. Post-poliomyelitis syndrome.Muscle Nerve 2005.PubMed 15599928 · doi:10.1002/mus.20259
  13. Tamarappoo BK, Klein AL. Post-pericardiotomy Syndrome.Curr Cardiol Rep 2016.PubMed 27761786 · doi:10.1007/s11886-016-0791-0
  14. Finsterer J. Primary periodic paralyses.Acta Neurol Scand 2008.PubMed 18031562 · doi:10.1111/j.1600-0404.2007.00963.x
  15. Lehto J, Kiviniemi T. Postpericardiotomy syndrome after cardiac surgery.Ann Med 2020.PubMed 32314595 · doi:10.1080/07853890.2020.1758339
  16. Tardelli VS, Bisaga A, Arcadepani FB, et al.. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.Psychopharmacology (Berl) 2020.PubMed 32601988 · doi:10.1007/s00213-020-05563-3

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.